Genscript Biotech Corporation (G51) — Cash Flow Reinvestment Rate
Genscript Biotech Corporation (G51) has a Cash Flow Reinvestment Rate of 0.00x as of December 2019, reinvesting €0.00 (capex €0.00 ) from operating cash flow of €61.62 Million. Check earnings quality score of Genscript Biotech Corporation to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Genscript Biotech Corporation Cash Flow Reinvestment Rate (2016–2025)
Historical reinvestment intensity for Genscript Biotech Corporation across 5 annual periods. Explore Genscript Biotech Corporation cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Genscript Biotech Corporation (2016–2025)
Year-by-year capital reinvestment analysis for Genscript Biotech Corporation. For live market cap and broader valuation context, see G51 company net worth.
| Year | Reinvestment Rate | Total Reinvested (EUR) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.45x | €147.45 Million | €325.52 Million | €83.84 Million | ▼ -96.4% |
| 2024 | 12.49x | €945.21 Million | €75.65 Million | €147.92 Million | ▲ +2502.3% |
| 2018 | 0.48x | €147.72 Million | €307.66 Million | €70.84 Million | ▼ -69.9% |
| 2017 | 1.60x | €34.09 Million | €21.37 Million | €29.21 Million | ▲ +206.9% |
| 2016 | 0.52x | €17.30 Million | €33.27 Million | €8.98 Million | — |